| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGER3 |
| Uniprot No | P43115 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-53 aa |
| 活性数据 | MKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSVSVA |
| 分子量 | 12.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于重组人PTGER3蛋白的3-4篇模拟参考文献的示例(内容基于文献研究领域常见方向虚构，仅供参考)：
---
1. **文献名称**: *Structural insights into ligand binding and activation of the human prostaglandin receptor EP3*
**作者**: Li, X. et al. (2021)
**摘要**: 通过冷冻电镜技术解析了人PTGER3(EP3受体)与内源性配体PGE2及G蛋白复合体的高分辨率结构，揭示了受体激活的构象变化机制，为靶向EP3的药物设计提供结构基础。
2. **文献名称**: *EP3 receptor signaling in cancer-associated fibroblasts promotes tumor angiogenesis via COX-2/PGE2 axis*
**作者**: Wang, Y. et al. (2022)
**摘要**: 研究证明重组人PTGER3在肿瘤微环境中通过激活COX-2/PGE2信号通路增强血管生成，靶向EP3受体可抑制小鼠模型中的肿瘤生长。
3. **文献名称**: *Pharmacological characterization of a novel EP3 receptor antagonist for neuropathic pain relief*
**作者**: Tanaka, K. et al. (2020)
**摘要**: 开发了一种新型PTGER3选择性拮抗剂，通过抑制脊髓中EP3受体介导的cAMP信号，显著减轻神经病理性疼痛模型的痛觉超敏反应。
4. **文献名称**: *EP3 receptor regulates β-cell survival in obesity-induced metabolic stress*
**作者**: Martinez, R. et al. (2023)
**摘要**: 利用重组人PTGER3蛋白发现EP3受体通过调节β细胞的内质网应激反应参与糖尿病发展，拮抗EP3可改善高脂饮食小鼠的胰岛素分泌功能。
---
*注：以上文献为示例性虚构内容，实际研究需查阅PubMed、ScienceDirect等数据库获取真实文献。*
**Background of Recombinant Human PTGER3 Protein**
Prostaglandin E receptor 3 (PTGER3), also known as EP3. is a G protein-coupled receptor (GPCR) that binds prostaglandin E2 (PGE₂), a lipid mediator involved in inflammation, pain, and cellular homeostasis. Encoded by the *PTGER3* gene, this receptor exists as multiple splice variants, leading to isoforms with distinct C-terminal domains that influence downstream signaling. PTGER3 primarily couples with inhibitory G proteins (Gᵢ/o), reducing intracellular cAMP levels, but can also activate other pathways, such as calcium mobilization, depending on context and isoform expression.
Recombinant human PTGER3 protein is produced using biotechnological systems (e.g., mammalian, insect, or bacterial cells) to enable controlled study of its structure, ligand interactions, and signaling mechanisms. This engineered protein retains functional epitopes and binding specificity, making it valuable for drug discovery, particularly in inflammatory diseases (e.g., arthritis), cancer (where PGE₂ promotes tumor progression), and cardiovascular disorders. Researchers use recombinant PTGER3 to screen therapeutics, map binding sites, or investigate cross-talk with other receptors. Its role in modulating immune responses and pain perception further highlights its therapeutic relevance. However, functional complexity due to splice variants necessitates isoform-specific studies, underscoring the importance of well-characterized recombinant proteins in advancing mechanistic and translational research.
×
